Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 3/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | GRM6 | O15303 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348734 | 1.00 | HSPB1 (0.40) | HSPB1L3MBTL1KCNMA1ALDH1A1HTT | |
| SCHEMBL3343328 | 0.88 | HSPB1 (0.41) | HSPB1L3MBTL1KCNMA1ALDH1A1HTT | |
| SCHEMBL27771907 | 0.87 | MAPT (0.43) | L3MBTL1ALDH1A1HTTMAPT | |
| SCHEMBL14260873 | 0.87 | MAPT (0.43) | L3MBTL1ALDH1A1HTTMAPT | |
| SCHEMBL8340048 | 0.87 | MAPT (0.43) | L3MBTL1ALDH1A1HTTMAPT | |
| SCHEMBL8340434 | 0.79 | MAPT (0.43) | L3MBTL1ALDH1A1HTTMAPT | |
| SCHEMBL14260875 | 0.79 | MAPT (0.43) | L3MBTL1ALDH1A1HTTMAPT | |
| SCHEMBL14367241 | 0.77 | MAPT (0.42) | L3MBTL1ALDH1A1HTTMAPTLMNA | |
| SCHEMBL14260874 | 0.77 | MAPT (0.42) | L3MBTL1ALDH1A1HTTMAPTLMNA | |
| SCHEMBL14260872 | 0.74 | MAPT (0.40) | L3MBTL1ALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | HSPB1 741/4885L3MBTL1 4126/4885KCNMA1 1781/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | HSPB1 227/4885L3MBTL1 4806/4885KCNMA1 136/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | HSPB1 1066/4885L3MBTL1 4401/4885KCNMA1 2047/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | HSPB1 4704/4885L3MBTL1 3933/4885KCNMA1 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.